This week in Drug Discovery (15 – 19 September)
News round-up for 15 – 19 September by Bruno Quinney, Content Team at DDW.
Stories from the drug discovery industry have continued to make headlines this week, with high-level investment from GSK in the US coming at a time when big pharma companies have halted investment in the UK. Elsewhere, there have been important developments in cancer research.
The top stories:
AstraZeneca halts £200m research investment in UK
AstraZeneca has halted its planned £200 ($270) million investment in a research facility in Cambridge, UK, according to reports from Reuters.
GSK to invest $30 billion in US over next five years
GSK will invest $30 billion (£22 billion) across the US over the next five years in research and development and supply chain infrastructure, the company has announced.
State-of-the-art life sciences hub opened in London
Victoria House has been officially opened in London’s Bloomsbury Square as the capital’s state-of-the-art life sciences hub.
New report calls for investment in UK research commercialisation
A new research report has found that investing £15 billion ($20 billion) in UK university spinouts over the next 10 years could leverage a further £27 billion ($39 billion) of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, boosting UK science on the global stage.
New data sheds light on immunotherapy failure in cancer patients
A new study has revealed an important clue as to why immunotherapy fails in many patients with cancer.
